US Pre-Market SEC Filings Roundup — October 14, 2026

13-10-2026

Control Empresarial de Capitales, S.A. de C.V., the holding vehicle of the Slim Family, filed Amendment No. 6 to its Schedule 13D disclosing that it beneficially owns 29,659,036 Common Shares of Talos Energy Inc. (TALO), representing 17.8% of outstanding shares as of October 13, 2026. The filing also discloses open-market sales of 8,940,000 shares between October 8 and October 13, 2026 at weighted average prices ranging from approximately $17.03 to $17.52. The filing reports a reduction in ownership activity via sales and does not disclose any acquisition, control change, or new strategic intent.

• · Aggregate open-market sales since Amendment No. 5 totaled 8,940,000 shares across four trading days (Oct 8, 9, 12, 13, 2026), with the largest single-day sale of 2,700,000 shares on October 13, 2026
• · Sale prices ranged from a low of $16.99 to a high of $17.725 across the reported trades
• · Filing was executed by Marco Antonio Slim Domit as Attorney-in-Fact under powers of attorney previously filed with PBF Energy Inc. Schedule 13D/A on March 4, 2026
• · Filing references a prior Amendment No. 5 dated September 17, 2026, while the amendment's own date and cover page are internally inconsistent (cover shows an earlier accession-year reference and an October 8, 2026 event date)

13-10-2026

Haymaker Sponsor IV LLC, its managing member Andrew R. Heyer, and Steven Heyer filed Amendment No. 1 to their Schedule 13D on Suncrete, Inc. (RMIX) reporting that a Sponsor distribution of 3,564,267 Class A shares and 75,000 private placement warrants to its members, effective October 8, 2026, caused each Reporting Person to cease owning more than 5% of Class A Common Stock. Andrew R. Heyer now reports beneficial ownership of 1,363,167 shares (2.8%) and Steven Heyer reports 309,774 shares (0.6%), with the Sponsor reporting zero. Each distributee that received securities signed a Joinder agreeing to continue the transfer restrictions of the Sponsor Support Agreement.

• · Andrew R. Heyer's holdings include 1,123,670 shares received in the Distribution, 48,000 restricted shares, and 175,852 shares plus 15,645 warrant shares held via Heyer Investment Management, LLC
• · Steven Heyer's holdings include 130,794 shares held directly and 178,980 shares held by The David H Heyer 2013 Trust, of which he is a co-trustee
• · Filing excludes shares held by Andrew Heyer's spouse and the Mindy B Heyer GRAT, which he disclaims beneficial ownership of
• · Percentages are based on 49,339,225 Class A shares outstanding as of August 10, 2026 per the Q2 2026 Form 10-Q

13-10-2026

Chief Executive Officer Ritchie Robert C sold 69,727 Common Stock at $27.12 (~$1.89M). Ritchie Robert C holds 1,760,433 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

• · Chief Executive Officer Ritchie Robert C sold 3,137 Common Stock at $27.05 (~$84.9K)
• · Chief Executive Officer Ritchie Robert C sold 69,727 Common Stock at $27.12 (~$1.89M)
• · Chief Executive Officer Ritchie Robert C sold 50,700 Common Stock at $27.41 (~$1.39M)

13-10-2026

SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold 500 Common Stock at $73.59 (~$36.8K). Cook Meredith holds 73,424 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

• · SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold 500 Common Stock at $73.59 (~$36.8K)

13-10-2026

CEO and Chairman Mukhija Manavdeep Singh was awarded 183,333 Common Stock, par value $0.0001 per share. Mukhija Manavdeep Singh holds 748,126 shares after the transaction.

• · CEO and Chairman Mukhija Manavdeep Singh was awarded 183,333 Common Stock, par value $0.0001 per share

13-10-2026

Chief Executive Officer Musunuri Shankar sold 468,727 Common Stock at $0.95 (~$445K). Musunuri Shankar holds 1,030,771 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

• · Chief Executive Officer Musunuri Shankar sold 468,727 Common Stock at $0.95 (~$445K)
• · Chief Executive Officer Musunuri Shankar sold 57,264 Common Stock at $0.95 (~$54.4K)

13-10-2026

KKR-affiliated entities filed Amendment No. 12 to their Schedule 13D disclosing that Independence Energy Aggregator L.P. purchased 40,000,000 shares of Crescent Energy Co (CRGY) Class A Common Stock at the $12.50 public offering price in an October 2026 underwritten offering of 80,000,000 shares (plus a 12,000,000-share underwriter option exercised in full). Following the offering's closing on October 13, 2026, the reporting persons collectively beneficially own 68,655,357 shares (16.3% of 422,456,708 outstanding Class A shares), with IE Aggregator holding 66,185,773 shares (15.7%). The filing is a passive-investment disclosure and notes a 60-day lock-up on the reporting persons' shares.

• · Lock-up restricts disposition or hedging of the reporting persons' Class A shares from October 8, 2026 through 60 days after the final prospectus supplement, absent consent from J.P. Morgan Securities LLC and KKR Capital Markets LLC
• · Filing states purchases were for investment purposes and the reporting persons may acquire or dispose of additional shares in the future
• · Source of funds was capital contributions from the reporting persons and/or their partners, members, and affiliates
• · Percentage ownership is based on the 424B3 prospectus filed October 13, 2026

13-10-2026

Chief Executive Officer PECK KRISTIN C was awarded 720.1441 Phantom Stock Unit at $26.17 (~$18.8K).

• · Chief Executive Officer PECK KRISTIN C was awarded 720.1441 Phantom Stock Unit at $26.17 (~$18.8K)

13-10-2026

CFO/CEO FRAKES JAMES B was awarded 42,000 Common Stock. FRAKES JAMES B holds 42,063 shares after the transaction.

• · CFO/CEO FRAKES JAMES B was awarded 42,000 Common Stock

13-10-2026

CFO & COO Maddox Charles K. acquired 18,345 Common Stock. Maddox Charles K. holds 18,345 shares after the transaction.

• · CFO & COO Maddox Charles K. acquired 18,345 Common Stock

13-10-2026

PFO and PAO Moore Daniel William sold 15,480 Class A Common Stock at $27.00 (~$418K). Moore Daniel William holds 92,348 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

• · PFO and PAO Moore Daniel William sold 15,480 Class A Common Stock at $27.00 (~$418K)

13-10-2026

See Remarks Heine Martin Andres bought 7,000 Class B Shares at $2.67 (~$18.7K). Heine Martin Andres holds 41,500 shares after the transaction.

• · See Remarks Heine Martin Andres bought 7,000 Class B Shares at $2.67 (~$18.7K)

13-10-2026

Director MERRIMAN D JONATHAN bought 4,700 Common Stock, $0.00001 par value at $2.08 (~$9.78K). MERRIMAN D JONATHAN holds 390,832 shares after the transaction.

• · Director MERRIMAN D JONATHAN bought 4,700 Common Stock, $0.00001 par value at $2.08 (~$9.78K)

13-10-2026

Chief Technology Officer Liborski Valeri was awarded 89,928 Restricted Stock Units.

• · Chief Technology Officer Liborski Valeri was awarded 89,928 Restricted Stock Units

13-10-2026

Director Kim Vyacheslav sold 20,631 American Depositary Shares, no par value at $92.61 (~$1.91M). 9 transactions reported in total. Trades executed under a Rule 10b5-1 plan.

• · Director Kim Vyacheslav sold 20,631 American Depositary Shares, no par value at $92.61 (~$1.91M)
• · Director Kim Vyacheslav sold 5,387 American Depositary Shares, no par value at $93.17 (~$502K)
• · Director Kim Vyacheslav sold 2,135 American Depositary Shares, no par value at $94.32 (~$201K)
• · Director Kim Vyacheslav sold 4,706 American Depositary Shares, no par value at $95.78 (~$451K)
• · Director Kim Vyacheslav sold 9,988 American Depositary Shares, no par value at $96.45 (~$963K)
• · Director Kim Vyacheslav sold 9,438 American Depositary Shares, no par value at $97.35 (~$919K)
• · Director Kim Vyacheslav sold 9,211 American Depositary Shares, no par value at $95.43 (~$879K)
• · Director Kim Vyacheslav sold 9,271 American Depositary Shares, no par value at $96.07 (~$891K)

13-10-2026

Avricore Health Inc. furnished a Form 6-K for September 2026 attaching a news release dated September 1, 2026 announcing that its HealthTab™ programme has expanded nationally across England. The filing itself contains no quantitative financial results, amounts, or period-over-period comparisons; the substantive content is limited to the expansion announcement referenced in the exhibit list.

• · Exhibit 1 is a news release titled 'HealthTab™ Programme Expands Nationally Across England', dated September 01, 2026
• · The filing is a Form 6-K for the month of September 2026, Commission File Number 000-51848
• · The registrant is a foreign private issuer that files Form 20-F (not Form 40-F) and has principal offices in Vancouver, BC
• · Filing was signed October 09, 2026 by CFO Kiki Smith, roughly five weeks after the underlying news release

13-10-2026

Braskem S.A. furnished a Form 6-K dated October 2026 (signed October 9, 2026) disclosing Article 11 (CVM Instruction #44/2021) trading of its securities by related persons in September 2026, including Group and Related Persons, Controlling Shareholders, the Board of Directors, Management, and the Fiscal Council, plus Technical or Advisory Bodies. The filing reports routine insider transactions and holdings: a 250 Class A Preferred Share purchase by the Board-related persons, small Management trades, and balances such as 438,761,574 and 123,055,912 shares in the reported categories. No financial results, guidance, or operational performance figures are disclosed.

• · Filing is a Form 6-K under Article 11 of CVM Instruction #44/2021 covering insider trading disclosure for September 2026
• · Filer checks Form 20-F as its annual report type and is not furnishing the information under Rule 12g3-2(b)
• · Several categories report no transactions during the month, indicating limited insider activity

13-10-2026

Brookfield Infrastructure Partners L.P. and Brookfield Infrastructure Corporation (BIPC) filed a Form 6-K for October 2026 furnishing Exhibit 99.1, a press release dated October 9, 2026. The filing itself is a cover document with signatures and an exhibit list; it contains no financial figures, operating metrics, or substantive disclosures in the body text. The substance of any announcement resides in the referenced press release, which was not included in the provided content.

• · Filing made under Form 20-F designation (registrant checked Form 20-F, not Form 40-F)
• · Principal executive offices listed as 73 Front Street, Fifth Floor, Hamilton, Bermuda and 250 Vesey Street, 15th Floor, New York, NY
• · Commission File Number 001-33632 (Partnership) and 000-56727 (Corporation)
• · Exhibit 99.1 is a press release dated October 9, 2026; its content is not included in the filing text provided

13-10-2026

Brookfield Renewable Partners L.P. (BEPJ) furnished a Form 6-K for October 2026 that attaches only Exhibit 99.1, a press release dated October 9, 2026. The cover page and signature block identify the registrant, a Bermuda-based foreign private issuer, and signatory James Bodi (President of the general partner). The filing body contains no financial figures, percentages, or operating metrics, so the substantive content resides in the unattached-in-text press release.

• · Filing references Exhibit 99.1, a press release dated October 9, 2026, but the press release text is not included in the provided content
• · Registrant is a foreign private issuer filing a 20-F annual report (Form 20-F box checked), Commission File Number 001-35530
• · Filing date (October 13, 2026) differs from the signature date (October 9, 2026)

13-10-2026

CL Workshop Group Limited (Nasdaq-listed, Macau-based) received notice from Nasdaq on September 16, 2026 that it has regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), closing the deficiency matter first disclosed May 8, 2026. Compliance was based on ADS closing bids at or above $1.00 for 10 consecutive business days, September 1 to September 15, 2026. The filing contains no financial results, revenue, or other quantitative operating data.

• · Original Nasdaq deficiency letter was dated May 6, 2026 and disclosed May 8, 2026
• · Filing is a Form 6-K for the month of October 2026, signed October 9, 2026
• · Company incorporates this report by reference into Form F-3 (File No. 333-297543) and Form S-8 (Registration No. 333-299186)

13-10-2026

CytoMed Therapeutics Limited received a Nasdaq notification on October 6, 2026, stating it is not in compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), after its ordinary shares traded below $1.00 for 30 consecutive business days from August 24, 2026 to October 5, 2026. The company has been granted a 180-calendar-day compliance period until April 5, 2027, to regain compliance, which requires a closing bid of at least $1.00 for ten consecutive business days; the notice does not immediately affect listing or trading.

• · Nasdaq listing rule cited: 5550(a)(2), minimum bid price of $1.00 per share
• · Notification letter received October 6, 2026; press release issued October 9, 2026 (Exhibit 99.1)
• · If the company cannot cure by April 5, 2027, it may qualify for a second compliance period if it meets market value of publicly held shares and other initial listing standards for the Nasdaq Capital Market, and provides written notice of intent to cure, potentially via reverse stock split
• · Company states it is actively monitoring the bid price and considering all available options

13-10-2026

Vale S.A. issued a clarification note on October 9, 2026 responding to media reports and social media statements about the July 22, 2026 Board sanction removing former Vice-Chairman Marcelo Gasparino da Silva for the deliberate leak of confidential June 19, 2026 Board meeting information. The company says an external investigation confirmed the leak, that Gasparino admitted sending a draft vote and statement to a market analyst, that the CVM has opened an administrative proceeding against him, and that Vale has served him a notice to cease disseminating statements and intends to pursue civil and criminal remedies. The filing also includes routine governance disclosures (politically exposed person declarations, shareholder meeting quorums, board resignations and appointments), with no financial performance figures reported.

• · Gasparino's removal was effective upon his resignation, which took effect August 1, 2026; the removal itself would have required shareholder confirmation at an Extraordinary General Meeting.
• · A Previ-requested Extraordinary General Meeting on removing Chairman Daniel Stieler was called following a June 11, 2026 request by a shareholder holding 7.01% of capital.
• · Stieler resigned as Chairman on July 6, 2026 and Wilfred Bruijn was elected interim Chairman on July 14, 2026.
• · The investigation found Gasparino's leaked vote was sent to more than one third party outside the company, and that he shared a summary of June 19 Board resolutions before the July 22 EGM notice was published.
• · Gasparino did not attend the July 22 Board meeting and declined repeated opportunities to be interviewed during the investigation.
• · The company filed an updated Reference Form (item 7.8) on October 9, 2026 with additional disclosure on these facts.
• · Vale says it will continue to provide information requested by the CVM and will pursue criminal measures alongside civil remedies.

13-10-2026

Vizsla Silver Corp. (VZLA) furnished a Form 6-K for October 2026 under the Securities Exchange Act, attaching three exhibits: a news release dated October 9, 2026, a report of voting results, and a 2026 Shareholder Rights Plan. The filing itself contains no financial figures, and the substantive content is contained in the attached exhibits, which are not reproduced in the filing text provided.

• · Filed as a Form 40-F filer (Canadian multijurisdictional disclosure system), Commission File Number 001-41225
• · Exhibit 99.1 is a news release dated October 9, 2026; Exhibit 99.2 is a report of voting results, likely from a shareholder meeting
• · Exhibit 99.3 is a 2026 Shareholder Rights Plan, which is typically an anti-takeover mechanism that can be material to shareholder rights and potential takeover dynamics

13-10-2026

Starry Sea Acquisition Corp (SSEAR) disclosed that its Extraordinary General Meeting, originally set for October 9, 2026, has been postponed to October 19, 2026 to allow more time for shareholder engagement. As of the October 7, 2026 redemption tabulation, 4,281,993 public shares had been submitted for redemption, leaving 1,468,007 public shares outstanding. The company is seeking to reverse approximately 350,174 redemption requests, which would bring outstanding public shares to at least 1,818,181 and keep the monthly extension contribution at the $60,000 cap.

• · Extraordinary General Meeting postponed from 10:00 a.m. ET on October 9, 2026 to 9:00 a.m. ET on October 19, 2026
• · Approximately 74.5% of public shares (4,281,993 of 5,750,000 implied) were submitted for redemption by the October 7, 2026 deadline, based on the post-redemption outstanding count
• · Company is soliciting reversal of about 350,174 redemption requests to reach at least 1,818,181 public shares outstanding
• · Filing is a soliciting material disclosure under Rule 14a-12, not a deal announcement

13-10-2026

Super League Enterprise filed a supplement (DEFA14A) to its September 25, 2026 definitive proxy statement for its 2026 Annual Meeting of Stockholders, to be held October 16, 2026. The supplement clarifies that the two Metaplanet Director Designees not yet identified will be determined by Metaplanet after the closing of the Metaplanet Transaction, rather than before. The Board's voting recommendations (FOR Proposal No. 1 Class III director nominees and FOR Proposals 2 through 7) are unchanged.

• · Metaplanet will designate the Chair of the Super League Board for so long as it is entitled to designate and nominate directors, with the Chair to be determined prior to the Closing
• · Metaplanet Director Designees serve until the next annual meeting or until successors are duly elected
• · The Board fills director vacancies using its authority under the Bylaws, appointing Metaplanet Director Designees to replace resigning directors

13-10-2026

Non Invasive Monitoring Systems Inc (NIMU) filed an amended S-1 registration statement dated October 13, 2026, covering financial data for the six months ended June 30, 2026 and the fiscal years through July 31, 2025. The filing discloses a pending merger agreement with Gravitics, Inc. (dated March 6, 2026, with an amendment referenced for August 5, 2026) and continued reliance on related-party promissory note financing from Frost Gamma Investments Trust and Dr. Jane Hsiao. The extracted text is primarily XBRL tagging metadata, so specific reported dollar amounts and period-over-period performance figures could not be reliably extracted.

• · Merger agreement between NIMU and Gravitics, Inc. dated March 6, 2026, with an amendment referenced as of August 5, 2026
• · Subsequent event dated July 27, 2026 disclosed in the filing
• · Convertible promissory note purchase agreement dated June 24, 2026 with a range of principal amounts referenced
• · New promissory note agreement with Dr. Jane Hsiao dated May 7, 2026
• · Multiple related-party promissory notes with Frost Gamma Investments Trust and Dr. Jane Hsiao, including notes dated 2021 through 2025 and a subsequent-event note dated January 5, 2026
• · Series Seed and Series A redeemable convertible preferred stock tied to Gravitics, Inc. are referenced in equity statements

13-10-2026

NuvOx Therapeutics, Inc. (NYSE American listing sought under symbol NUOX) filed Amendment No. 2 to its Form S-1 registration statement for an initial public offering of 2,860,000 shares of common stock, with an anticipated price range of $6.00 to $8.00 per share and a 45-day over-allotment option for up to 429,000 additional shares. The clinical-stage biopharmaceutical company is developing NanO2, an intravenously administered oxygen therapeutic whose API is dodecafluoropentane, for hypoxia-related diseases. The offering is contingent on NYSE American listing approval, and the filing discloses no revenue, earnings, or other financial performance figures in the excerpt provided.

• · Registration No. 333-297520; Amendment No. 2 to Form S-1, dated October 9, 2026 and filed October 13, 2026
• · Company is an emerging growth company and smaller reporting company electing reduced reporting requirements
• · Underwriter/representative is ThinkEquity; underwriting discount and proceeds table left blank pending pricing
• · Risk Factors begin on page 17; Underwriting section on page 165
• · NanO2 converts from emulsified liquid to gas at body temperature, delivering more oxygen than in liquid state
• · Target indications include diseases where hypoxia plays a critical role; glossary references GBM, TBI, ARDS, ALS, and MI

13-10-2026

SPACCircle Acquisition Corp., a Cayman Islands blank-check company, filed an amended S-1 registration statement for an IPO of 15,000,000 units, each containing one Class A ordinary share, one warrant exercisable at $11.50, and one share right entitling the holder to one-third of a Class A ordinary share upon completion of a business combination. A simultaneous private placement of 254,090 units is planned, and the sponsor paid $25,000 for 5,750,000 founder shares, of which up to 750,000 are subject to forfeiture depending on over-allotment exercise. The filing is a blank-check structure with no operating business and no proceeds yet deployed, and it contains no reported financial performance results, so the sentiment is neutral.

• · Separate trading of shares, warrants and share rights is prohibited until a Form 8-K with an audited balance sheet reflecting receipt of gross proceeds is filed.
• · Warrants become exercisable 30 days after the initial business combination and expire five years after completion or earlier upon redemption or liquidation.
• · Warrants are redeemable at $0.01 each if the closing price is at least $18.00 for 20 of 30 trading days, starting 150 days after the business combination.
• · Only Class B holders vote on director appointment/removal before the business combination and on any continuation outside the Cayman Islands.
• · Share rights expire worthless if no business combination is completed and public shares are redeemed from the trust account.
• · The filing references a registration number 333-298956 and an earlier signature date of October 9, 2026, versus the October 13, 2026 filing date.

13-10-2026

VME Companies, Inc. filed an amended S-1 registration statement (S-1/A) in connection with a proposed Nasdaq IPO. Upon completion, Vinson-Shea Holdings, Ltd. (controlled by CEO Michael Thomas) and Kole & Marlee Holdings, Ltd. (controlled by COO Kuoh Lee) will hold a majority of voting power, making VME a 'controlled company' that will rely on exemptions from certain Nasdaq governance requirements. The filing also discloses litigation with aggregate potential exposure of approximately $17 million, partially offset by approximately $26.5 million in pending claims and counterclaims, a mixed risk picture for prospective investors.

• · Post-IPO, the two controlling holding companies will hold a majority of voting power, allowing exemption from Nasdaq requirements for a majority-independent board and fully independent compensation and nominating committees
• · Controlling stockholders may take actions (dividends, related-party transactions, corporate governance) that diverge from other shareholders' interests
• · The company has no current securities analyst coverage, and future downgrades or lack of coverage could pressure the share price
• · Company relies on patents and IP, but notes enforcement is difficult and litigation may take years; patents may be invalidated by the USPTO or foreign equivalents
• · Company faces risk from new technologies by competitors that could displace its products and services
• · Potential exposure from tax audits and disputes in multiple jurisdictions could materially increase worldwide taxes
• · Accounting estimates and possible restatements could materially affect reported financial condition

13-10-2026

Health In Tech, Inc. (HIT), a Nevada AI-enabled insurance technology marketplace for stop-loss policies, filed Amendment No. 1 to its Form S-3 registration statement to register resale of shares issuable under a Standby Equity Purchase Agreement (SEPA) with Yorkville. The SEPA provides up to $20.0 million of Class A common stock sales at the Company's option, with up to $15.0 million of pre-paid advances funded via Convertible Notes. The filing is a resale registration with no obligation on the Company to draw funds, and it introduces potential dilution through conversion and advance shares.

• · Yorkville may purchase Advance Shares at 97% of the lowest daily VWAP in the Pricing Period, creating a built-in discount that can pressure the share price.
• · Share count reduces by one-third for each trading day with an excluded VWAP, which can change proceeds for a given Advance.
• · Advance Maximum Amount is capped at 100% of the five-day average daily Nasdaq trading volume, limiting sizes relative to liquidity.
• · The Company is under no obligation to sell shares or draw advances, so the $20.0M commitment is an option rather than committed funding.
• · The Company holds an 85.72% economic interest and 28.58% voting interest in HITChain Inc., incorporated January 2, 2026, indicating a controlled but economically diluted subsidiary structure.
• · Anchor 36, LLC and HITRix, LLC were formed as wholly-owned subsidiaries in September 2026.
• · The company is an emerging growth company and smaller reporting company, permitting reduced disclosure and two years of audited financials.

14-10-2026

Verastem Oncology announced that Michael P. Bailey will succeed Daniel Paterson as President and CEO effective January 1, 2027, as part of a planned succession plan. Paterson, who served as CEO since 2023 and with the company since 2011 (15-year tenure per the release), will retire, remain on the Board, and serve as an advisor. The company highlighted commercial progress for AVMAPKI FAKZYNJA CO-PACK and clinical advancement of VS-7375, though the release contains no financial results or quantitative performance figures.

• · Bailey has served on Verastem's Board since May 2026 and previously led AVEO as CEO from January 2015, including the FOTIVDA approval and launch in 2021
• · VS-7375 is in registration-directed Phase 2 trials (TARGET-D 201 in pancreatic, 202 in NSCLC, 203 in colorectal) and a Phase 3 trial in first-line metastatic pancreatic cancer is expected to begin later in 2026
• · VS-7375 holds FDA Fast Track Designation for KRAS G12D-mutated PDAC (first-line and previously treated) and previously treated NSCLC
• · AVMAPKI FAKZYNJA CO-PACK received accelerated FDA approval on May 8, 2025 for KRAS-mutated recurrent LGSOC; continued approval may depend on a confirmatory trial
• · Paterson will remain on the Board and as an advisor after stepping down as CEO

14-10-2026

Fearless Solutions, LLC dba Best Invest (San Antonio, TX) filed a Form 13F-HR for the period ended September 30, 2026, disclosing 143 holdings with a reported total portfolio value of approximately $196.5 billion (196,522,046 thousand dollars per the cover page's reported table value). The portfolio is concentrated in large-cap technology and ETFs, with Apple, Alphabet, Amazon, and Blackstone among the largest individual positions. Because the filing covers holdings only, it contains no period-over-period performance comparison, and it does not disclose changes from the prior quarter.

• · Largest disclosed positions by value are Apple (~$10.1B), Amazon (~$5.0B), Blackstone (~$3.8B), and Alphabet Class A (~$3.3B), with ETFs forming a substantial share of the holdings.
• · Holdings include a broad mix of individual equities and exchange-traded funds spanning equity, fixed income, commodity, and sector exposures.
• · The filing is signed by Aryn Sands as agent, with the report dated October 14, 2026.

14-10-2026

Focus Financial Network, Inc. (CIK 0002010942, Minneapolis, MN) filed a Form 13F-HR on October 14, 2026 for the quarter ended September 30, 2026, disclosing its equity and fund holdings in an institutional information table. The excerpt provided is truncated, so only a partial list of positions is visible; the largest visible positions include Amazon (289,543 shares), Apple (339,213 shares), and Alphabet Class A (88,182 shares). No period-over-period comparison is available in the filing excerpt, so performance trends cannot be assessed.

• · Filing is for the reporting period ended September 30, 2026, filed October 14, 2026 under SEC file number 028-24075.
• · Holdings are reported with sole investment discretion and no shared or other-manager voting authority in the visible rows.
• · The visible portion of the information table includes numerous ETF positions across multiple issuers (iShares/BlackRock, First Trust, AIM ETF Products Trust, Fidelity, Dimensional), indicating a diversified, index- and ETF-heavy portfolio.
• · Visible convertible note positions (Affirm, Akamai, DexCom, DoorDash) are small in face value (≈$10,000–$12,000 thousand principal per the table).
• · The information table is truncated in the provided excerpt; total portfolio value, total position count, and any position changes versus the prior quarter cannot be determined from this content.